ArticleExperimental hematology & oncology2013
The forgotten tale of immunoglobulin allotypes in cancer risk and treatment.
Article in Experimental hematology & oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Immunoglobulin γ allotypes influence the level of autoantibody responses to amyloid-β in patients with Alzheimer's disease.Human immunology · 2026Article
- Roles of immunoglobulin GM and KM allotypes and Fcγ receptor 2 A genotypes in humoral immunity to a conserved microbial polysaccharide in pulmonary diseases.Genes and immunity · 2025Article
- Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer's disease in African Americans.Immunogenetics · 2024Article
- Identification of IgG1 and IgG3 Allotypes by PCR and Sanger Sequencing.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Immunoglobulin γ marker genes as effect modifiers of Epstein-Barr virus-multiple sclerosis association.Immunology · 2023Article
- Immunoglobulin GM and KM allotypes are associated with antibody responses to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Beyond Allotypes: The Influence of Allelic Diversity in Antibody Constant Domains.Frontiers in immunology · 2020Review
- Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.Journal of virology · 2019Article
- Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis.Frontiers in immunology · 2019Review
- Unveiling the Diversity of Immunoglobulin Heavy Constant Gamma (Frontiers in immunology · 2019Article
- Endogenous antibody responses to mucin 1 in a large multiethnic cohort of patients with breast cancer and healthy controls: Role of immunoglobulin and Fcγ receptor genes.Immunobiology · 2018Article
- Association of immunoglobulin GM allotypes with longevity in long-living individuals from Southern Italy.Immunity & ageing : I & A · 2018Article
- Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma.Neuro-oncology · 2015Article
- Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.Arthritis research & therapy · 2015Article
- Genetic variants of immunoglobulin γ and κ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.Clinical and experimental immunology · 2014Article
- Immunoglobulin GM Genes, Cytomegalovirus Immunoevasion, and the Risk of Glioma, Neuroblastoma, and Breast Cancer.Frontiers in oncology · 2014Review
- Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.Oncoimmunology · 2014Article
- Cancer immunotherapy: are we there yet?Experimental hematology & oncology · 2013Article
- Immunoglobulin genes implicated in glioma risk.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibody (mAb) has fulfilled the promise of being the "Magic Bullet" in oncology with the clinical success of mAbs against CD20, Her-2/neu, epidermal growth factor receptor, vascular endothelial cell growth factor and others in a variety of cancers. Most manufacturers of mouse-human chimeric antibodies (and most immunologists) have treated the constant region of human immunoglobulin (Ig) as if it were naturally monomorphic and therefore not immunogenic in humans. In fact, the constant region of Ig heavy and light chain is highly polymorphic, and yet Ig haplotypes are usually not defined by genome-wide association studies nor are they considered to be important for optimizing mAb therapy. We hereby summarize evidence that Ig allotypes are important and biologically relevant in that they contribute to the etiopathogenesis of many malignant, infectious, and autoimmune diseases. Because Ig allotypes differ from each other in engaging Fc receptor, we argue that future development of effective mAb therapy for cancer should take a patient-specific approach by using the correct allotype for each patient to maximize the efficacy of this therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.